Cocrystal Pharma (NASDAQ:COCP – Get Free Report) released its earnings results on Monday. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02), FiscalAI reports. The firm had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.10 million.
Cocrystal Pharma Stock Performance
Shares of Cocrystal Pharma stock opened at $0.98 on Monday. Cocrystal Pharma has a 1 year low of $0.76 and a 1 year high of $2.03. The firm has a market capitalization of $18.88 million, a PE ratio of -1.29 and a beta of 1.60. The firm’s 50 day moving average is $1.08 and its 200 day moving average is $1.10.
Analysts Set New Price Targets
COCP has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Cocrystal Pharma in a research note on Friday, October 9th. Weiss Ratings cut Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cocrystal Pharma has an average rating of “Hold”.
Check Out Our Latest Stock Analysis on Cocrystal Pharma
About Cocrystal Pharma
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.
Featured Articles
- Five stocks we like better than Cocrystal Pharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
